Current Status of Dapagliflozin in Congestive Heart Failure

Heart failure is a prominent clinical condition and a top concern as a widespread health issue. The incidence of heart failure is rising alarmingly on a global scale. Heart failure significantly strains the whole healthcare system financially, degrading the patient's quality of life and increasing the risk of morbidity and mortality. Heart failure treatment has changed over time with ongoing research and the development of new medications and equipment. Recently, the FDA and European Union (EU) approved the drug dapagliflozin, which is an inhibitor of sodium-glucose cotransporter 2 (SGLT-2i), for treating people with cardiovascular conditions and symptomatic heart failure (HF). In this review article, we will find out whether Dapagliflozin, when given at a dose of 10 mg/day in people with type 2 diabetes and in those without type 2 diabetes who have or are at risk for atherosclerotic alterations, can considerably lower the risk of cardiovascular mortality or hospitalization for HF. In the presence of concomitant HF therapies, dapagliflozin's benefits remained. Dapagliflozin's overall safety profile was comparable to its safety profile for other applications. It was often well tolerated in patients in a study group. In this review article, dapagliflozin is found to be the well -tolerated and effective novel treatment of choice for symptomatic HF. Because of the scarcity of research on dapagliflozin, it was necessary to provide data to help reduce the mortality of patients while providing further guidance on the clinical medication of dapagliflozin.